News
VNRX
0.1715
-14.25%
-0.0285
VolitionRX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
VolitionRX Price Target Cut to $1.00/Share From $1.50 by HC Wainwright & Co.
Dow Jones · 1d ago
VolitionRx: Robust Revenue Growth and Promising Capture-Seq Data Support Buy Rating Despite Dilution-Driven Target Cut
TipRanks · 1d ago
VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright
TipRanks · 1d ago
HC Wainwright & Co. Maintains Buy on VolitionRX, Lowers Price Target to $1
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL), Annexon Biosciences (ANNX) and VolitionRX (VNRX)
TipRanks · 1d ago
VolitionRx Shareholders Approve Stock Issuance and Reverse Split
TipRanks · 2d ago
VolitionRx anticipates France routine Nu.Q Cancer use by Q4 2026 while targeting 25%-30% 2026 cash OpEx reduction
Seeking Alpha · 2d ago
VolitionRX reports FY results
Seeking Alpha · 2d ago
VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate
Benzinga · 3d ago
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
PR Newswire · 3d ago
VolitionRx Limited secures €2M non-dilutive funding from Belgian agencies
Seeking Alpha · 3d ago
VolitionRX Is Maintained at Buy by D. Boral Capital
Dow Jones · 3d ago
VolitionRX Price Target Maintained With a $3.00/Share by D. Boral Capital
Dow Jones · 3d ago
VolitionRx Secures €2 Million Funding To Advance Nu.Q Diagnostics And Expand Access In Low-Income Markets
Benzinga · 3d ago
Earnings Scheduled For March 31, 2026
Benzinga · 3d ago
VolitionRx Announces The Publication Of A New Clinical Manuscript Demonstrating That Nucleosome Levels, As Measured By Volition's Nu.Q H3.1 And Nu.Q H3R8 Citrulline Are Elevated In People That Have Experienced A Traumatic Event And Are Even Higher In Those Patients That Go On To Have Complications From The Trauma
Benzinga · 4d ago
Weekly Report: what happened at VNRX last week (0323-0327)?
Weekly Report · 4d ago
VolitionRX Is Maintained at Buy by D. Boral Capital
Dow Jones · 03/26 18:48
VolitionRX Price Target Maintained With a $3.00/Share by D. Boral Capital
Dow Jones · 03/26 18:48
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.